+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Respiratory Diseases Drugs Global Market Report 2020-30: COVID-19 Implications and Growth

  • ID: 5028652
  • Report
  • May 2020
  • Region: Global
  • The Business Research Company

FEATURED COMPANIES

  • AstraZeneca Plc
  • GlaxosmithKline Plc
  • Johnson & Johnson
  • Merck & Co
  • Novartis AG
Respiratory Diseases Drugs Global Market Report 2020-30: COVID-19 Implications and Growth from the publisher covers this critical market and the impact on it from the COVID-19 virus. It provides strategists, marketers and senior management with the critical information they need to assess the increasing demand for respiratory diseases drugs which play a critical role in the treatment of patients with COVID-19.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market is experiencing rapid growth due to the coronavirus and how it is likely to stabilize as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3 working days of order.
Description:
Where is the largest and fastest growing market for the respiratory diseases drugs market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Respiratory Diseases Drugs Market global report from the publisher answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider respiratory diseases drugs market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The respiratory diseases drugs market section of the report gives context. It compares the respiratory diseases drugs market with other segments of the respiratory diseases drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, respiratory diseases drugs indicators comparison.
Scope

Markets Covered:
1) By Type: Anti-Asthmatics And COPD Drugs; Cough And Cold Preparations
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/ Drug Stores; Others
3) By Route Of Administration: Oral; Parenteral; Others
4) By Drug Classification: Branded Drugs; Generic Drugs
5) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs

Companies Mentioned: GlaxosmithKline Plc; AstraZeneca Plc; Merck & Co; Novartis AG; Johnson & Johnson

Metrics Covered: Number of Enterprises; Number of Employees

Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, respiratory diseases drugs indicators comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca Plc
  • GlaxosmithKline Plc
  • Johnson & Johnson
  • Merck & Co
  • Novartis AG
1. Executive Summary

2. Report Structure

3. Respiratory Diseases Drugs Market Characteristics
3.1. Market Definition
3.2. Key Segmentations

4. Respiratory Diseases Drugs Market Product Analysis
4.1. Leading Products/ Services
4.2. Key Features and Differentiators
4.3. Development Products

5. Respiratory Diseases Drugs Market Supply Chain
5.1. Supply Chain
5.2. Distribution
5.3. End Customers

6. Respiratory Diseases Drugs Market Customer Information
6.1. Customer Preferences
6.2. End Use Market Size and Growth

7. Respiratory Diseases Drugs Market Trends And Strategies

8. Respiratory Diseases Drugs Market Size And Growth
8.1. Market Size
8.2. Historic Market Growth, Value ($ Billion)
8.2.1. Drivers Of The Market
8.2.2. Restraints On The Market
8.3. Forecast Market Growth, Value ($ Billion)
8.3.1. Drivers Of The Market
8.3.2. Restraints On The Market

9. Respiratory Diseases Drugs Market Regional Analysis
9.1. Global Respiratory Diseases Drugs Market, 2019, By Region, Value ($ Billion)
9.2. Global Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Historic And Forecast, By Region
9.3. Global Respiratory Diseases Drugs Market, Growth And Market Share Comparison, By Region

10. Respiratory Diseases Drugs Market Segmentation
10.1. Global Respiratory Diseases Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Anti-Asthmatics And COPD Drugs
  • Cough And Cold Preparations
10.2. Global Respiratory Diseases Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies/ Drug Stores
  • Others
10.3. Global Respiratory Diseases Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Oral
  • Parenteral
  • Others
10.4. Global Respiratory Diseases Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Branded Drugs
  • Generic Drugs
10.5. Global Respiratory Diseases Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Prescription-Based Drugs
  • Over-The-Counter Drugs
11. Respiratory Diseases Drugs Market Metrics
11.1. Respiratory Diseases Drugs Market Size, Percentage Of GDP, 2015-2023, Global
11.2. Per Capita Average Respiratory Diseases Drugs Market Expenditure, 2015-2023, Global

12. Asia-Pacific Respiratory Diseases Drugs Market
12.1. Asia-Pacific Respiratory Diseases Drugs Market Overview
12.2. Asia-Pacific, Respiratory Diseases Drugs Market, 2019, By Country, Value ($ Billion)
12.3. Asia-Pacific, Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Historic And Forecast, By Country
12.4. Asia-Pacific, Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Growth And Market Share Comparison, By Country
12.5. Asia-Pacific, Respiratory Diseases Drugs Market Metrics
12.5.1. Per Capita Average Respiratory Diseases Drugs Expenditure, 2015-2023, Asia-Pacific Countries
12.5.2. Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2019, Asia-Pacific Countries
12.6. Asia-Pacific Respiratory Diseases Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7. Asia-Pacific Respiratory Diseases Drugs Market: Country Analysis
12.7.1. China Respiratory Diseases Drugs Market
12.7.1.1. China Respiratory Diseases Drugs Market Overview
12.7.1.2. China Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.1.3. China Respiratory Diseases Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.2. Australia Respiratory Diseases Drugs Market
12.7.2.1. Australia Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.2.2. Australia Respiratory Diseases Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.3. Hong Kong Respiratory Diseases Drugs Market
12.7.3.1. Hong Kong Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.4. India Respiratory Diseases Drugs Market
12.7.4.1. India Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.4.2. India Respiratory Diseases Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.5. Indonesia Respiratory Diseases Drugs Market
12.7.5.1. Indonesia Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.5.2. Indonesia Respiratory Diseases Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.6. Japan Respiratory Diseases Drugs Market
12.7.6.1. Japan Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.6.2. Japan Respiratory Diseases Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.7. Malaysia Respiratory Diseases Drugs Market
12.7.7.1. Malaysia Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.8. New Zealand Respiratory Diseases Drugs Market
12.7.8.1. New Zealand Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.9. Philippines Respiratory Diseases Drugs Market
12.7.9.1. Philippines Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.10. Singapore Respiratory Diseases Drugs Market
12.7.10.1. Singapore Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.11. South Korea Respiratory Diseases Drugs Market
12.7.11.1. South Korea Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.11.2. South Korea Respiratory Diseases Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.12. Thailand Respiratory Diseases Drugs Market
12.7.12.1. Thailand Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.13. Vietnam Respiratory Diseases Drugs Market
12.7.13.1. Vietnam Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)

13. Western Europe Respiratory Diseases Drugs Market
13.1. Western Europe Respiratory Diseases Drugs Market Overview
13.2. Western Europe, Respiratory Diseases Drugs Market, 2019, By Country, Value ($ Billion)
13.3. Western Europe, Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Historic And Forecast, By Country
13.4. Western Europe, Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Growth And Market Share Comparison, By Country
13.5. Western Europe, Respiratory Diseases Drugs Market Metrics
13.5.1. Per Capita Average Respiratory Diseases Drugs Expenditure, 2015-2023, Western Europe Countries
13.5.2. Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2019, Western Europe Countries
13.6. Western Europe Respiratory Diseases Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7. Western Europe Respiratory Diseases Drugs Market: Country Analysis
13.7.1. Austria Respiratory Diseases Drugs Market
13.7.1.1. Austria Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.2. Belgium Respiratory Diseases Drugs Market
13.7.2.1. Belgium Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.3. Denmark Respiratory Diseases Drugs Market
13.7.3.1. Denmark Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.4. Finland Respiratory Diseases Drugs Market
13.7.4.1. Finland Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.5. France Respiratory Diseases Drugs Market
13.7.5.1. France Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.5.2. France Respiratory Diseases Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.6. Germany Respiratory Diseases Drugs Market
13.7.6.1. Germany Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.6.2. Germany Respiratory Diseases Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.7. Ireland Respiratory Diseases Drugs Market
13.7.7.1. Ireland Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.8. Italy Respiratory Diseases Drugs Market
13.7.8.1. Italy Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.9. Netherlands Respiratory Diseases Drugs Market
13.7.9.1. Netherlands Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.10. Norway Respiratory Diseases Drugs Market
13.7.10.1. Norway Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.11. Portugal Respiratory Diseases Drugs Market
13.7.11.1. Portugal Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.12. Spain Respiratory Diseases Drugs Market
13.7.12.1. Spain Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.13. Sweden Respiratory Diseases Drugs Market
13.7.13.1. Sweden Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.14. Switzerland Respiratory Diseases Drugs Market
13.7.14.1. Switzerland Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.15. UK Respiratory Diseases Drugs Market
13.7.15.1. UK Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.15.2. UK Respiratory Diseases Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)

14. Eastern Europe Respiratory Diseases Drugs Market
14.1. Eastern Europe Respiratory Diseases Drugs Market Overview
14.2. Eastern Europe, Respiratory Diseases Drugs Market, 2019, By Country, Value ($ Billion)
14.3. Eastern Europe, Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Historic And Forecast, By Country
14.4. Eastern Europe, Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Growth And Market Share Comparison, By Country
14.5. Eastern Europe, Respiratory Diseases Drugs Market Metrics
14.5.1. Per Capita Average Respiratory Diseases Drugs Expenditure, 2015-2023, Eastern Europe Countries
14.5.2. Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2019, Eastern Europe Countries
14.6. Eastern Europe Respiratory Diseases Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
14.7. Eastern Europe Respiratory Diseases Drugs Market: Country Analysis
14.7.1. Czech Republic Respiratory Diseases Drugs Market,
14.7.1.1. Czech Republic Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
14.7.2. Poland Respiratory Diseases Drugs Market
14.7.2.1. Poland Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
14.7.3. Romania Respiratory Diseases Drugs Market
14.7.3.1. Romania Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
14.7.4. Russia Respiratory Diseases Drugs Market
14.7.4.1. Russia Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
14.7.4.2. Russia Respiratory Diseases Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)

15. North America Respiratory Diseases Drugs Market
15.1. North America Respiratory Diseases Drugs Market Overview
15.2. North America, Respiratory Diseases Drugs Market, 2019, By Country, Value ($ Billion)
15.3. North America, Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Historic And Forecast, By Country
15.4. North America, Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Growth And Market Share Comparison, By Country
15.5. North America, Respiratory Diseases Drugs Market Metrics
15.5.1. Per Capita Average Respiratory Diseases Drugs Expenditure, 2015-2023, North America Countries
15.5.2. Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2019, North America Countries
15.6. North America Respiratory Diseases Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
15.7. North America Respiratory Diseases Drugs Market: Country Analysis
15.7.1. Canada Respiratory Diseases Drugs Market
15.7.1.1. Canada Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
15.7.2. Mexico Respiratory Diseases Drugs Market
15.7.2.1. Mexico Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
15.7.3. USA Respiratory Diseases Drugs Market
15.7.3.1. USA Respiratory Diseases Drugs Market Overview
15.7.3.2. USA Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
15.7.3.3. USA Respiratory Diseases Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)

16. South America Respiratory Diseases Drugs Market
16.1. South America Respiratory Diseases Drugs Market Overview
16.2. South America, Respiratory Diseases Drugs Market, 2019, By Country, Value ($ Billion)
16.3. South America, Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Historic And Forecast, By Country
16.4. South America, Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Growth And Market Share Comparison, By Country
16.5. South America, Respiratory Diseases Drugs Market Metrics
16.5.1. Per Capita Average Respiratory Diseases Drugs Expenditure, 2015-2023, South America Countries
16.5.2. Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2019, South America Countries
16.6. South America Respiratory Diseases Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
16.7. South America Respiratory Diseases Drugs Market: Country Analysis
16.7.1. Argentina Respiratory Diseases Drugs Market
16.7.1.1. Argentina Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
16.7.2. Brazil Respiratory Diseases Drugs Market
16.7.1.1. Brazil Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
16.7.2.2. Brazil Respiratory Diseases Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
16.7.3. Chile Respiratory Diseases Drugs Market
16.7.3.1. Chile Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
16.7.4. Colombia Respiratory Diseases Drugs Market
16.7.4.1. Colombia Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
16.7.5. Peru Respiratory Diseases Drugs Market
16.7.5.1. Peru Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
16.7.6. Venezuela Respiratory Diseases Drugs Market
16.7.6.1. Venezuela Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)

17. Middle East Respiratory Diseases Drugs Market
17.1. Middle East Respiratory Diseases Drugs Market Overview
17.2. Middle East, Respiratory Diseases Drugs Market, 2019, By Country, Value ($ Billion)
17.3. Middle East, Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Historic And Forecast, By Country
17.4. Middle East, Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Growth And Market Share Comparison, By Country
17.5. Middle East, Respiratory Diseases Drugs Market Metrics
17.5.1. Per Capita Average Respiratory Diseases Drugs Expenditure, 2015-2023, Middle East Countries
17.5.2. Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2019, Middle East Countries
17.6. Middle East Respiratory Diseases Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
17.7. Middle East Respiratory Diseases Drugs Market: Country Analysis
17.7.1. Saudi Arabia Respiratory Diseases Drugs Market
17.7.1.1. Saudi Arabia Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
17.7.2. Israel Respiratory Diseases Drugs Market
17.7.2.1. Israel Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
17.7.3. Turkey Respiratory Diseases Drugs Market
17.7.3.1. Turkey Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
17.7.4. UAE Respiratory Diseases Drugs Market
17.7.4.1. UAE Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)

18. Africa Respiratory Diseases Drugs Market
18.1. Africa Respiratory Diseases Drugs Market Overview
18.2. Africa, Respiratory Diseases Drugs Market, 2019, By Country, Value ($ Billion)
18.3. Africa, Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Historic And Forecast, By Country
18.4. Africa, Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Growth And Market Share Comparison, By Country
18.5. Africa, Respiratory Diseases Drugs Market Metrics
18.5.1. Per Capita Average Respiratory Diseases Drugs Expenditure, 2015-2023, Africa Countries
18.5.2. Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2019, Africa Countries
18.6. Africa Respiratory Diseases Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
18.7. Africa Respiratory Diseases Drugs Market: Country Analysis
18.7.1. Egypt Respiratory Diseases Drugs Market
18.7.1.1. Egypt Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
18.7.2. Nigeria Respiratory Diseases Drugs Market
18.7.2.1. Nigeria Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
18.7.3. South Africa Respiratory Diseases Drugs Market
18.7.3.1. South Africa Respiratory Diseases Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)

19. Respiratory Diseases Drugs Market Competitive Landscape
19.1. Competitive Market Overview
19.2. Market Shares
19.3. Company Profiles
19.3.1. GlaxosmithKline Plc
19.3.1.1. Company Overview
19.3.1.2. Products And Services
19.3.1.3. Strategy
19.3.1.4. Financial Performance
19.3.2. AstraZeneca Plc
19.3.2.1. Company Overview
19.3.2.2. Products And Services
19.3.2.3. Strategy
19.3.2.4. Financial Performance
19.3.3. Merck & Co
19.3.3.1. Company Overview
19.3.3.2. Products And Services
19.3.3.3. Strategy
19.3.3.4. Financial Performance
19.3.4. Novartis AG
19.3.4.1. Company Overview
19.3.4.2. Products And Services
19.3.4.3. Strategy
19.3.4.4. Financial Performance
19.3.5. Johnson & Johnson
19.3.5.1. Company Overview
19.3.5.2. Products And Services
19.3.5.3. Strategy
19.3.5.4. Financial Performance

20. Key Mergers And Acquisitions In The Respiratory Diseases Drugs Market

21. Market Background: Pharmaceutical Drugs Market
21.1. Pharmaceutical Drugs Market Characteristics
21.2. Pharmaceutical Drugs Market Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F Growth, By Segment, Value ($ Billion), Global
21.3. Global Pharmaceutical Drugs Market, 2019, By Region, Value ($ Billion)
21.4. Global Pharmaceutical Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Historic And Forecast, By Region
21.5. Global Pharmaceutical Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Segmentation By Type, Value ($ Billion)

22. Recommendations
22.1. Global Respiratory Diseases Drugs Market In 2023- Growth Countries
22.2. Global Respiratory Diseases Drugs Market In 2023- Growth Segments
22.3. Global Respiratory Diseases Drugs Market In 2023- Growth Strategies

23. Appendix
23.1. NAICS Definitions Of Industry Covered In This Report
23.2. Abbreviations
23.3. Currencies
23.4. Research Inquiries
23.5. About the Publisher

24. Copyright And Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca Plc
  • GlaxosmithKline Plc
  • Johnson & Johnson
  • Merck & Co
  • Novartis AG
North America was the largest region in the global respiratory diseases drugs market, accounting for 49% of the market in 2019. Western Europe was the second largest region accounting for 19% of the global respiratory diseases drugs market. Africa was the smallest region in the global respiratory diseases drugs market.

The demand for PSE-containing cold, allergy, and sinus products is growing due to their effectiveness and convenience. PSE is an active ingredient found in various cold, allergy, and sinus drugs that can provide congestion relief. However, PSE-containing medicines are mostly sold as a prescription drug, as PSE can also be used for the illegal manufacture of methamphetamine, a recreational drug. This has led drug manufacturers to produce tamper-resistant PSE products. For instance, in March 2017, pharmaceutical companies Acura Pharmaceuticals Inc. and MainPointe Pharmaceuticals LLC entered into an agreement, enabling MainPointe Pharmaceuticals LLC to market NEXAFED and NEXAFED Sinus products in the US and Canada. These drugs utilize tamper-resistant PSE formulation to prevent the illicit production of methamphetamine.

The respiratory diseases drugs market consists of sales of respiratory diseases drugs and related services by entities (organizations, sole traders and partnerships) that produce drugs to treat respiratory diseases such as asthma, acute bronchitis, emphysema, cystic fibrosis and other diseases. This industry includes establishments that produce anti-asthmatics and COPD drugs to prevent acute attacks caused by respiratory diseases and cough and cold preparations to treat cough and cold.

The global respiratory diseases drugs market is expected to grow from $65 billion in 2019 to $92.6 billion in 2020 at a compound annual growth rate (CAGR) of 42.5%. The respiratory drugs market witnessed significant growth mainly due to the COVID-19 outbreak. The fact that Covid-19 is essentially a respiratory ailment has boosted the market growth. Drugs such as Albuterol have registered high growth. The market is then expected to stabilize and grow at a CAGR of 4% from 2021 and reach $97.8 billion in 2023.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • GlaxosmithKline Plc
  • AstraZeneca Plc
  • Merck & Co
  • Novartis AG
  • Johnson & Johnson
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll